169206-67-1 Usage
General Description
Tert-Butyl 3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate is a chemical compound with the molecular formula C14H25NO3. It is a derivative of spiro compounds, which are characterized by a unique carbon framework with two or more rings sharing a single carbon atom. This particular compound is a spirocyclic lactam ester, containing a tertiary butyl group and a carboxylate functional group. It is commonly used in organic synthesis and medicinal chemistry as a building block for the creation of new compounds with potential pharmaceutical applications. The structure and properties of tert-Butyl 3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate make it an interesting and versatile molecule for the development of new drugs and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 169206-67-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,2,0 and 6 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 169206-67:
(8*1)+(7*6)+(6*9)+(5*2)+(4*0)+(3*6)+(2*6)+(1*7)=151
151 % 10 = 1
So 169206-67-1 is a valid CAS Registry Number.
InChI:InChI=1/C13H22N2O3/c1-12(2,3)18-11(17)15-6-4-13(5-7-15)8-10(16)14-9-13/h4-9H2,1-3H3,(H,14,16)
169206-67-1Relevant articles and documents
QUINAZOLINE COMPOUND FOR EGFR INHIBITION
-
Paragraph 0173; 0176, (2019/11/21)
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2016/05/19)
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Spiro aryl phosphorus oxide or sulfide
-
Paragraph 0228; 0229; 0230; 0231, (2016/10/08)
The invention discloses a spiro aryl phosphorus oxide or sulfide as ALK inhibitor, and in particular discloses a compound shown in a formula (I) as an ALK inhibitor or a pharmaceutically acceptable salt thereof.
